Figure 1.

Studies reporting the presence of myelin oligodendrocyte glycoprotein (MOG) antibodies (Abs) in patients with inflammatory demyelinating disorders (A) MS; (B) ADEM; (C) AQP4− ON/TM/NMOSD; (D) AQP4+ NMOSD (sensitivity, left side of each graph) in comparison to a control group of patients with other neurological disorders and/or healthy controls (specificity, right side of each graph). Sensitivities and specificities are indicated by symbols with error bars (95% confidence intervals). Specificities were calculated using the frequency of MOG Abs in other neurological disorders or healthy controls determined by the methods shown in Table 4. Sensitivities were calculated using the frequency of MOG Abs in inflammatory demyelinating disorders determined by the methods shown in Table 4.